445 results about "Polypeptide composition" patented technology

The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules.

Disclosed are novel synthetically-modified B. thuringiensis nucleic acid segments encoding delta -endotoxins having insecticidal activity against lepidopteran insects. Also disclosed are synthetic crystal proteins encoded by these novel nucleic acid sequences. Methods of making and using these genes and proteins are disclosed as well as methods for the recombinant expression, and transformation of suitable host cells. Transformed host cells and transgenic plants expressing the modified endotoxin are also aspects of the invention. Also disclosed are methods for modifying, altering, and mutagenizing specific loop regions between the alpha helices in domain 1 of these crystal proteins, including Cry1C, to produce genetically-engineered recombinant cry* genes, and the proteins they encode which have improved insecticidal activity. In preferred embodiments, novel Cry1C* amino acid segments and the modified cry1C* nucleic acid sequences which encode them are disclosed.

The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules.

Compositions and methods for protecting a plant from a pathogen, particularly a fungal pathogen, are provided. Compositions include novel amino acid sequences, and variants and fragments thereof, for antipathogenic polypeptides that were isolated from microbial fermentation broths. Nucleic acid molecules comprising nucleotide sequences that encode the antipathogenic polypeptides of the invention are also provided. A method for inducing pathogen resistance in a plant using the nucleotide sequences disclosed herein is further provided. The method comprises introducing into a plant an expression cassette comprising a promoter operably linked to a nucleotide sequence that encodes an antipathogenic polypeptide of the invention. Compositions comprising an antipathogenic polypeptide or a transformed microorganism comprising a nucleic acid of the invention in combination with a carrier and methods of using these compositions to protect a plant from a pathogen are further provided. Transformed plants, plant cells, seeds, and microorganisms comprising a nucleotide sequence that encodes an antipathogenic polypeptide of the invention, or variant or fragment thereof, are also disclosed.

A novel gene encoding a Coleopteran inhibitory Bacillus thuringiensis insecticidal crystal protein is disclosed. The protein, tIC851, is insecticidally active and provides plant protection from at least cotton boll weevil, Anthomomus grandis, when applied to plants in an insecticidally effective composition.

A CD20-binding polypeptide composition comprising a combination of a modified heavy chain variable region polypeptide and a modified light chain variable region polypeptide. The combination can be (a) a modified 2B8 antibody heavy chain variable region polypeptide of SEQ ID NO: 48; and a modified 2B8 antibody light chain variable region polypeptide of SEQ ID NO: 49; or (b) a modified Leu16 antibody heavy chain variable region polypeptide of SEQ ID NO: 50; and a modified Leu16 antibody light chain variable region polypeptide of SEQ ID NO: 51.

The present invention relates to purified peptidomimetic macrocycles. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications.

The invention discloses polypeptide composition with skin activity for the problems of various wrinkles and ageing of skin. The composition comprises a combination of polypeptides with argireline effects and polypeptides with effects of promoting the generation of skin proteins and improving the skin, wherein the concentrations of the polypeptides are all 0.01 ppm to 5,000 ppm. The composition provided by the invention can be used for quickly smoothening the wrinkles, reducing the wrinkle depth, promoting the generation of various skin matrix proteins and enabling the skin to be compact, elastic, full and smooth.

The invention provides a polypeptide composition for skin whitening and spot relieving. The polypeptide composition comprises an MC1-R antagonist (namely an alpha-MSH competitive antagonist) and / or a composition of polypeptides inhibiting alpha-MSH expression and / or a tyrosinase inhibitor. The polypeptide composition can reduce the generation of melanin, and contributes to skin brightening, so as to achieve the purposes of relieving color spots (chloasma, butterfly rash, freckle and the like), improving sallow tone and whitening skin. The concentration of each polypeptide is 0.0001-5%. The polypeptide composition provided by the invention can be prepared into various beauty and skin-care products as well as medical products.

A TNF alpha-binding polypeptide composition comprises at least one of a modified heavy chain variable region polypeptide or a modified light chain variable region polypeptide that is capable of specifically binding to human TNF alpha. The modified heavy chain variable region polypeptide and the modified light chain variable region polypeptide each are homologous to respective heavy chain or light chain variable regions of a non-human monoclonal antibody that specifically binds to human TNF alpha. The amino acid residue sequence of at least one of the modified heavy chain variable region polypeptide and the modified light chain variable region polypeptide differs from the amino acid residue sequence of the respective non-human monoclonal antibody heavy chain variable regions or light chain variable regions by at least one amino acid residue substitution, deletion or addition. The polypeptide compositions of the invention are less immunogenic to a human than an antibody comprising the same human constant regions and having heavy chain and light chain variable regions identical to the respective heavy chain and light chain variable regions of said non-human monoclonal antibody.